Checkpoint inhibitors for Glioblastoma – pro
PG and PD – L inhibitors are currently being studied against many tumor types, including glioblastoma. Initial findings from clinical trials separately exploring the safety and efficacy of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as potential treatments for patients with glioblastoma are promising. Findings from separate trials exploring the PD-1 inhibitor pembrolizumab (Keytruda) and the PD-L1 inhibitor durvalumab (MEDI4736) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme (GBM), based on encouraging efficacy signals and safety data with the two agents reported at the 21st Society for Neuro-Oncology (SNO) Annual Scientific Meeting.
However, these studies are still ongoing, for exampe, there is Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma, NCT02337686. Therefore, this is still an Experimental and not medically necessary approach
Matthias Preusser, Michael Lim, David A. Hafler, David A. Reardon, and John H. Sampson
Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015 Sep; 11(9): 504514.
Huang B et al, Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res. 2017;2017:3597613.
Keytruda, prescribing Information, 2017
NCCN, Brain-D, 1 2017